3 Stocks Improving Performance Of The Drugs Industry
All three major indices are trading up today with the
Dow Jones Industrial Average
(
^DJI
) trading up 37 points (0.2%) at 17,877 as of Wednesday, July 6, 2016, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,655 issues advancing vs. 1,273 declining with 140 unchanged.
The Drugs industry currently sits up 0.8% versus the S&P 500, which is up 0.3%. Top gainers within the industry include
(
), up 3.7%,
(
), up 3.7%,
(
), up 3.3%,
(
), up 3.1% and
(
), up 2.7%.
TheStreet would like to highlight 3 stocks pushing the industry higher today:
3.
(
) is one of the companies pushing the Drugs industry higher today. As of noon trading, Biogen is up $4.22 (1.7%) to $246.25 on average volume. Thus far, 874,882 shares of Biogen exchanged hands as compared to its average daily volume of 1.9 million shares. The stock has ranged in price between $240.71-$246.83 after having opened the day at $241.01 as compared to the previous trading day's close of $242.03.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
Biogen Inc. discovers, develops, manufactures, and delivers therapies for the treatment of neurodegenerative diseases, hematologic conditions, and autoimmune disorders. Biogen has a market cap of $53.7 billion and is part of the health care sector. Shares are down 21.0% year-to-date as of the close of trading on Tuesday. Currently there are 12 analysts who rate Biogen a buy, no analysts rate it a sell, and 5 rate it a hold.
TheStreet Ratings rates
Biogen
as a
. The company's strengths can be seen in multiple areas, such as its impressive record of earnings per share growth, increase in net income, revenue growth, largely solid financial position with reasonable debt levels by most measures and reasonable valuation levels. We feel its strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full
now.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
2. As of noon trading,
(
) is up $0.92 (1.6%) to $58.92 on average volume. Thus far, 6.4 million shares of Merck exchanged hands as compared to its average daily volume of 8.9 million shares. The stock has ranged in price between $58.07-$58.99 after having opened the day at $58.27 as compared to the previous trading day's close of $58.00.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
Merck & Co., Inc. provides health care solutions worldwide. Merck has a market cap of $160.4 billion and is part of the health care sector. Shares are up 9.8% year-to-date as of the close of trading on Tuesday. Currently there are 5 analysts who rate Merck a buy, no analysts rate it a sell, and 7 rate it a hold.
TheStreet Ratings rates
Merck
as a
. The company's strengths can be seen in multiple areas, such as its increase in net income, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, expanding profit margins and increase in stock price during the past year. We feel its strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full
now.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
1. As of noon trading,
Valeant Pharmaceuticals International
(
) is up $1.94 (9.7%) to $21.89 on average volume. Thus far, 22.1 million shares of Valeant Pharmaceuticals International exchanged hands as compared to its average daily volume of 32.0 million shares. The stock has ranged in price between $19.61-$22.08 after having opened the day at $20.08 as compared to the previous trading day's close of $19.95.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
Valeant Pharmaceuticals International, Inc. develops, manufactures, and markets pharmaceuticals, over-the-counter products, and medical devices worldwide. Valeant Pharmaceuticals International has a market cap of $7.0 billion and is part of the health care sector. Shares are down 80.4% year-to-date as of the close of trading on Tuesday. Currently there are 4 analysts who rate Valeant Pharmaceuticals International a buy, 3 analysts rate it a sell, and 8 rate it a hold.
TheStreet Ratings rates
Valeant Pharmaceuticals International
as a
. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, generally high debt management risk, disappointing return on equity, generally disappointing historical performance in the stock itself and feeble growth in its earnings per share. Get the full
Valeant Pharmaceuticals International Ratings Report
now.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider
(
) while those bearish on the drugs industry could consider
ProShares UltraShort Nasdaq Biotech
(
).